Dr. Reddy's Laboratories Ltd. (DRREDDY) Stock Forecast & Price Target

Compare

6 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

DRREDDY Analyst Ratings

Moderate Buy

2 Buy

0 Hold

1 Sell

Based on 3 analysts giving stock ratings to

Dr.

Reddy's Laboratories Ltd.

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

DRREDDY Stock 12 Month Forecast

Average Price Target

₹1,433.33

▲(11.94% Upside)

Based on 3 Wall Street analysts offering 12 month price targets for Dr. Reddy's Laboratories Ltd. in the last 3 months. The average price target is ₹1,433.33 with a high forecast of ₹1,600.00 and a low forecast of ₹1,250.00. The average price target represents a 11.94% change from the last price of ₹1,280.40.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1109":"₹1,109","1232":"₹1,232","1355":"₹1,355","1478":"₹1,478","1601":"₹1,601"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1600,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹1.60K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1433.3333333333333,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹1.43K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1250,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹1.25K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1109,1232,1355,1478,1601],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1260,1286.1538461538462,1312.3076923076924,1338.4615384615386,1364.6153846153845,1390.7692307692307,1416.923076923077,1443.076923076923,1469.2307692307693,1495.3846153846155,1521.5384615384614,1547.6923076923076,1573.8461538461538,{"y":1600,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1260,1273.3333333333333,1286.6666666666667,1300,1313.3333333333333,1326.6666666666665,1340,1353.3333333333333,1366.6666666666665,1380,1393.3333333333333,1406.6666666666665,1420,{"y":1433.3333333333333,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1260,1259.2307692307693,1258.4615384615386,1257.6923076923076,1256.923076923077,1256.1538461538462,1255.3846153846155,1254.6153846153845,1253.8461538461538,1253.076923076923,1252.3076923076924,1251.5384615384614,1250.7692307692307,{"y":1250,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1266.22,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1213.75,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1213.75,"date":1733011200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1360.87,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1110.61,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1145.14,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1175.54,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1241.23,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1268.9,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1219.6,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1280.3,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1246.25,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1260,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target₹1,600

Average Price Target₹1,433

Lowest Price Target₹1,250

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Neha Manpuria

Bank of America Securities

₹1,600

Buy

24.96%

Upside

Reiterated

12/15/25

Bank of America Securities Keeps Their Buy Rating on Dr. Reddy's Laboratories Ltd. (DRREDDY)

Damayanti Kerai

HSBC

₹1,400→₹1,450

Buy

13.25%

Upside

Reiterated

10/14/25

HSBC Keeps Their Buy Rating on Dr. Reddy's Laboratories Ltd. (DRREDDY)

Alankar Garude

Kotak Mahindra

₹1,250

Sell

-2.37%

Downside

Reiterated

09/29/25

Kotak Mahindra Keeps Their Sell Rating on Dr. Reddy's Laboratories Ltd. (DRREDDY)

Bansi Desai

J.P. Morgan

₹1,090→₹1,150

Sell

-10.18%

Downside

Reiterated

08/19/25

J.P. Morgan Keeps Their Sell Rating on Dr. Reddy's Laboratories Ltd. (DRREDDY)

Saion Mukherjee

Nomura

₹1,575→₹1,660

Buy

29.65%

Upside

Reiterated

07/25/25

Nomura Sticks to Its Buy Rating for Dr. Reddy's Laboratories Ltd. (DRREDDY)

Abdulkader Puranwala

ICICI Securities

₹1,100→₹1,200

Hold

-6.28%

Downside

Reiterated

07/24/25

Dr. Reddy's Laboratories Ltd. (DRREDDY) Receives a Hold from ICICI Securities

Alok Dalal

Jefferies

₹1,010→₹1,100

Sell

-14.09%

Downside

Reiterated

07/24/25

Dr. Reddy's Laboratories Ltd. (DRREDDY) Gets a Sell from Jefferies

Shyam Srinivasan

Goldman Sachs

₹1,175→₹1,200

Hold

-6.28%

Downside

Reiterated

07/24/25

Dr. Reddy's Laboratories Ltd. (DRREDDY) Receives a Hold from Goldman Sachs

Binay Singh

Morgan Stanley

₹1,298

Hold

1.37%

Upside

Initiated

07/14/25

Dr. Reddy's Laboratories Ltd. (DRREDDY) Has a New Rating from Morgan Stanley

Kunal Dhamesha

Macquarie

₹1,450→₹1,190

Hold

-7.06%

Downside

Downgraded

07/08/25

Dr. Reddy's Laboratories Ltd. (DRREDDY) was downgraded to a Hold Rating at Macquarie

Vivek Agrawal CFA

Citi

₹1,040→₹990

Sell

-22.68%

Downside

Reiterated

06/27/25

Citi Keeps Their Sell Rating on Dr. Reddy's Laboratories Ltd. (DRREDDY)

Kunal Lakhan

CLSA

₹1,140→₹1,090

Sell

-14.87%

Downside

Downgraded

01/23/25

CLSA Downgrades Dr. Reddy's Laboratories (DRRD:IN) (RDY) to Underperform (4)CLSA analyst Kunal Lakhan downgraded Dr. Reddy's Laboratories (DRRD:IN) (NYSE: RDY) from Hold (3) to Underperform (4) with a price target of INR1,090.00 (from INR1,140.00).

Shrikant Akolkar

Nuvama

₹1,553

Buy

21.29%

Upside

Upgraded

01/07/25

Nuvama upgrades Dr. Reddy\s Laboratories (DRRD:LN) (RDY) to BuyNuvama analyst Shrikant Akolkar upgraded Dr. Reddy\s Laboratories (DRRD:LN) (NYSE: RDY) from Reduce to Buy with a price target of INR1,553.00.

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Neha Manpuria

Bank of America Securities

₹1,600

Buy

24.96%

Upside

Reiterated

12/15/25

Bank of America Securities Keeps Their Buy Rating on Dr. Reddy's Laboratories Ltd. (DRREDDY)

Damayanti Kerai

HSBC

₹1,400→₹1,450

Buy

13.25%

Upside

Reiterated

10/14/25

HSBC Keeps Their Buy Rating on Dr. Reddy's Laboratories Ltd. (DRREDDY)

Alankar Garude

Kotak Mahindra

₹1,250

Sell

-2.37%

Downside

Reiterated

09/29/25

Kotak Mahindra Keeps Their Sell Rating on Dr. Reddy's Laboratories Ltd. (DRREDDY)

Bansi Desai

J.P. Morgan

₹1,090→₹1,150

Sell

-10.18%

Downside

Reiterated

08/19/25

J.P. Morgan Keeps Their Sell Rating on Dr. Reddy's Laboratories Ltd. (DRREDDY)

Saion Mukherjee

Nomura

₹1,575→₹1,660

Buy

29.65%

Upside

Reiterated

07/25/25

Nomura Sticks to Its Buy Rating for Dr. Reddy's Laboratories Ltd. (DRREDDY)

Abdulkader Puranwala

ICICI Securities

₹1,100→₹1,200

Hold

-6.28%

Downside

Reiterated

07/24/25

Dr. Reddy's Laboratories Ltd. (DRREDDY) Receives a Hold from ICICI Securities

Alok Dalal

Jefferies

₹1,010→₹1,100

Sell

-14.09%

Downside

Reiterated

07/24/25

Dr. Reddy's Laboratories Ltd. (DRREDDY) Gets a Sell from Jefferies

Shyam Srinivasan

Goldman Sachs

₹1,175→₹1,200

Hold

-6.28%

Downside

Reiterated

07/24/25

Dr. Reddy's Laboratories Ltd. (DRREDDY) Receives a Hold from Goldman Sachs

Binay Singh

Morgan Stanley

₹1,298

Hold

1.37%

Upside

Initiated

07/14/25

Dr. Reddy's Laboratories Ltd. (DRREDDY) Has a New Rating from Morgan Stanley

Kunal Dhamesha

Macquarie

₹1,450→₹1,190

Hold

-7.06%

Downside

Downgraded

07/08/25

Dr. Reddy's Laboratories Ltd. (DRREDDY) was downgraded to a Hold Rating at Macquarie

Vivek Agrawal CFA

Citi

₹1,040→₹990

Sell

-22.68%

Downside

Reiterated

06/27/25

Citi Keeps Their Sell Rating on Dr. Reddy's Laboratories Ltd. (DRREDDY)

Kunal Lakhan

CLSA

₹1,140→₹1,090

Sell

-14.87%

Downside

Downgraded

01/23/25

Shrikant Akolkar

Nuvama

₹1,553

Buy

21.29%

Upside

Upgraded

01/07/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Dr. Reddy's Laboratories Ltd.

1 Month

xxx

Success Rate

2/3 ratings generated profit

Average Return

+1.50%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +1.50% per trade.

3 Months

xxx

Success Rate

2/3 ratings generated profit

Average Return

+1.00%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +1.00% per trade.

1 Year

Damayanti KeraiHSBC

Success Rate

3/3 ratings generated profit

Average Return

+1.87%

reiterated a buy rating 2 months ago

Copying Damayanti Kerai's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +1.87% per trade.

2 Years

xxx

Success Rate

3/3 ratings generated profit

Average Return

+1.87%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +1.87% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

DRREDDY Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, DRREDDY has received 7 Buy Ratings, 0 Hold Ratings, and 1 Sell Ratings. DRREDDY average Analyst price target in the past 3 months is 1,433.33.

Each month's total comprises the sum of three months' worth of ratings.

DRREDDY Financial Forecast

DRREDDY Earnings Forecast

Next quarter’s earnings estimate for DRREDDY is ₹14.86 with a range of ₹13.00 to ₹17.80. The previous quarter’s EPS was ₹17.25. DRREDDY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year DRREDDY has Performed in-line its overall industry.

DRREDDY Sales Forecast

Next quarter’s sales forecast for DRREDDY is ₹84.38B with a range of ₹82.20B to ₹87.40B. The previous quarter’s sales results were ₹88.05B. DRREDDY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year DRREDDY has Performed in-line its overall industry.

DRREDDY Stock Forecast FAQ

What is IN:DRREDDY’s average 12-month price target, according to analysts?

Based on analyst ratings, Dr. Reddy's Laboratories Ltd.’s 12-month average price target is 1,433.33.

What is IN:DRREDDY’s upside potential, based on the analysts’ average price target?

Dr. Reddy's Laboratories Ltd. has 11.94% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Dr. Reddy's Laboratories Ltd. a Buy, Sell or Hold?

Dr. Reddy's Laboratories Ltd. has a consensus rating of Moderate Buy, which is based on 2 buy ratings, 0 hold ratings and 1 sell ratings.

What is Dr. Reddy's Laboratories Ltd.’s share price target?

The average share price target for Dr. Reddy's Laboratories Ltd. is 1,433.33. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is ₹1,600.00 ,and the lowest forecast is ₹1,250.00. The average share price target represents 11.94% Increase from the current price of ₹1,280.4.

What do analysts say about Dr. Reddy's Laboratories Ltd.?

Dr. Reddy's Laboratories Ltd.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 3 Wall Streets Analysts.

How can I buy shares of Dr. Reddy's Laboratories Ltd.?

To buy shares of IN:DRREDDY, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Dr. Reddy's Laboratories Ltd. (DRREDDY) Stock Forecast & Price Target

DRREDDY Analyst Ratings

DRREDDY Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Dr. Reddy's Laboratories Ltd.

DRREDDY Analyst Recommendation Trends

DRREDDY Financial Forecast

DRREDDY Earnings Forecast

DRREDDY Sales Forecast

DRREDDY Stock Forecast FAQ

Detailed List of Analyst Forecasts